Synvista Therapeutics, Inc.

OTCPK:SYNI Stock Report

Market Cap: US$258.0

Synvista Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure17.9yrs

Recent management updates

No updates

Recent updates

No updates


CEO

Synvista Therapeutics has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Mary Tanner
Independent Director18.5yrsUS$89.14kno data
Bertram Pitt
Medical & Clinical Advisorno datano datano data
Noah Berkowitz
Director18.5yrsUS$445.08kno data
John Bedard
Independent Director17.3yrsUS$70.02kno data
Michael Zile
Medical & Clinical Advisorno datano datano data
William Little
Medical & Clinical Advisorno datano datano data
Dalane Kitzman
Medical & Clinical Advisorno datano datano data
Scott D. Solomon
Medical & Clinical Advisorno datano datano data
David Greenblatt
Medical & Clinical Advisorno datano datano data
William Federiciz
Director16.3yrsno datano data

17.9yrs

Average Tenure

71yo

Average Age

Experienced Board: SYNI's board of directors are seasoned and experienced ( 17.9 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 15:18
End of Day Share Price 2024/11/11 00:00
Earnings2008/09/30
Annual Earnings2007/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Synvista Therapeutics, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rahul JasujaMDB Capital Group LLC
Ashok KumarRodman & Renshaw, LLC